Open AccessAdenovirus‐mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma
Author(s) -
Iida Tomonori,
Shiba Hiroaki,
Misawa Takeyuki,
Ohashi Toya,
Eto Yoshikatsu,
Yanaga Katsuhiko
Publication year - 2008
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2008.00953.x
Subject(s) - humoral immunity , immunity , immune system , genetic enhancement , cellular immunity , hepatocellular carcinoma , cd40 , immunology , cancer research , viral vector , medicine , biology , cytotoxic t cell , gene , in vitro , biochemistry , recombinant dna
Adenoviral‐vector expressing CD40L (AxCAmCD40L)‐mediated gene therapy was studied for treatment of hepatocellular carcinoma (HCC) using CD40 ligand (CD40L) complementary DNA in rats. The particular focus was whether humoral immunity took part in antitumor effect. When tumor cells transduced by AxCAmCD40L were implanted into the subcutaneous tissues of syngeneic rats, the tumor growth was suppressed. Intratumoral injection of AxCAmCD40L to pre‐existing tumor in rats also led to significant reduction of tumor size. When tumor cells were re‐implanted to prevention model rats and treatment model rats, no tumor growth was observed. Many studies to date have reported that cellular immunity induces antitumor immunity. However, the present study demonstrated that not only cellular immunity but also humoral immunity plays an essential role in a HCC model. These observations suggested that CD40L‐mediated immune gene therapy for HCC was very effective treatment by activation of both cellular and humoral immune system. ( Cancer Sci 2008; 99: 2097–2103)